G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$4.11 USD
-0.06 (-1.44%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $4.12 +0.01 (0.24%) 6:38 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
GTHX 4.11 -0.06(-1.44%)
Will GTHX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GTHX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GTHX
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: Should You Buy?
GTHX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will G1 Therapeutics (GTHX) Report Negative Earnings Next Week? What You Should Know
G1 Therapeutics (GTHX) Tops Q2 Earnings and Revenue Estimates
G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates
Other News for GTHX
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
Buy Rating for G1 Therapeutics: Market Position and Growth Potential Solidify Investment Appeal
12 Health Care Stocks Moving In Monday's Pre-Market Session
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference